Brief: Everest Medicines Inks Agreement With Micot To Commercialize MT1013
05/02/2026 01:29
Feb 5 (Reuters) - Everest Medicines Ltd 1952.HK: AGREEMENT WITH MICOT TO COMMERCIALIZE MT1013 IN GREATER CHINA AND OTHER ASIAN MARKETS UNIT'S PAYMENT OBLIGATIONS INCLUDE AN UPFRONT PAYMENT OF RMB200 MLN, OTHERS Further company coverage: 1952.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region